Rare Diseases Expert Talks about Research in Duchenne Treatments
April 20, 2014

Email

The families of patients who suffer from Duchenne muscular dystrophy have pressured the FDA to approve a potential new drug that, so far, appears to have halted physical decline. Eric Hoffman, PhD, Director for the Research Center for Genetic Medicine, discusses Duchenne muscular dystrophy and the FDA's work on approving the drug with the Washington Post.